Company Registration No. 13048719 (England and Wales)
Occam Bio Limited
Unaudited financial statements
for the year ended 31 December 2025
Pages for filing with the registrar
Occam Bio Limited
Contents
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 7
Occam Bio Limited
Statement of financial position
As at 31 December 2025
1
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
7,300
5,100
Current assets
Debtors
5
49,530
110,729
Cash at bank and in hand
64,373
56,246
113,903
166,975
Creditors: amounts falling due within one year
6
(26,053)
(62,848)
Net current assets
87,850
104,127
Total assets less current liabilities
95,150
109,227
Provisions for liabilities
(1,688)
(1,158)
Net assets
93,462
108,069
Capital and reserves
Called up share capital
80
80
Profit and loss reserves
93,382
107,989
Total equity
93,462
108,069

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Occam Bio Limited
Statement of financial position (continued)
As at 31 December 2025
2
The financial statements were approved by the board of directors and authorised for issue on 13 May 2026 and are signed on its behalf by:
Ms Ana Montero Horas
Director
Company Registration No. 13048719
Occam Bio Limited
Notes to the financial statements
For the year ended 31 December 2025
3
1
Accounting policies
Company information

Occam Bio Limited is a private company limited by shares incorporated in England and Wales. The registered office is 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 40 1 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.

Occam Bio Limited is a wholly owned subsidiary of Occam BCI, Inc and the results of Occam Bio Limited are included in the consolidated financial statements of Occam BCI, Inc. The consolidated financial statements are held at 600 California Street, Fl 11, Ste 12028, San Francisco, CA 94108.

1.2
Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reliably measured. Turnover is recognised at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes for the provision of brain computer software services.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment
33.33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Occam Bio Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
1
Accounting policies (continued)
4
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Share Capital

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Occam Bio Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
1
Accounting policies (continued)
5
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.8
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense when employees have rendered the service entitling them to the contributions.

1.9
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

1.10
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Critical accounting judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

No significant judgements or estimates have been made during the year.

3
Employees

The average monthly number of persons (including remunerated directors) employed by the company during the year was:

2025
2024
Number
Number
Total
6
5
Occam Bio Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
6
4
Tangible fixed assets
Computer equipment
£
Cost
At 1 January 2025
13,329
Additions
5,622
At 31 December 2025
18,951
Depreciation and impairment
At 1 January 2025
8,229
Depreciation charged in the year
3,422
At 31 December 2025
11,651
Carrying amount
At 31 December 2025
7,300
At 31 December 2024
5,100
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
21
-
0
Amounts owed by group undertakings
44,327
104,575
Other debtors
5,182
6,154
49,530
110,729
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
7,702
-
0
Amounts owed to group undertakings
-
0
41,101
Taxation and social security
-
0
6,566
Other creditors
18,351
15,181
26,053
62,848
Occam Bio Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
7
7
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Sales
Sales
2025
2024
£
£
Entities with control, joint control or significant influence over the company
1,232,429
957,665

The following amounts were outstanding at the reporting end date:

2025
2024
Amounts due to related parties
£
£
Entities over which the entity has control, joint control or significant influence
-
41,101
2025
2024
Amounts due from related parties
£
£
Entities with control, joint control or significant influence over the company
159,827
104,575
8
Parent company

Occam Bio Limited is a wholly owned subsidiary of Occam BCI Inc, which is the ultimate controlling party, incorporated in Delaware, United States of America.

2025-12-31 2025-01-01 false false false 13 May 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity A Montero Horas Mr A F M Smith 13048719 2025-01-01 2025-12-31 13048719 2025-12-31 13048719 2024-12-31 13048719 core:ComputerEquipment 2025-12-31 13048719 core:ComputerEquipment 2024-12-31 13048719 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 13048719 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13048719 core:CurrentFinancialInstruments 2025-12-31 13048719 core:CurrentFinancialInstruments 2024-12-31 13048719 core:ShareCapital 2025-12-31 13048719 core:ShareCapital 2024-12-31 13048719 core:RetainedEarningsAccumulatedLosses 2025-12-31 13048719 core:RetainedEarningsAccumulatedLosses 2024-12-31 13048719 bus:Director1 2025-01-01 2025-12-31 13048719 core:ComputerEquipment 2025-01-01 2025-12-31 13048719 2024-01-01 2024-12-31 13048719 core:ComputerEquipment 2024-12-31 13048719 core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity core:SaleOrPurchaseGoods 2025-01-01 2025-12-31 13048719 core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity core:SaleOrPurchaseGoods 2024-01-01 2024-12-31 13048719 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 13048719 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 13048719 bus:FRS102 2025-01-01 2025-12-31 13048719 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 13048719 bus:Director2 2025-01-01 2025-12-31 13048719 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP